Literature DB >> 16860493

Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma.

Lorena Losi1, Giovanni Ponti, Carmela Di Gregorio, Massimiliano Marino, Giuseppina Rossi, Monica Pedroni, Piero Benatti, Luca Roncucci, Maurizio Ponz de Leon.   

Abstract

Patients with stage I colorectal cancer have a good prognosis, however, a small fraction of them die of local or distant recurrence after curative resection. The aggressive behavior reflects some biological properties of these tumors. In this study, we evaluated the prognostic role of some histopathological and biological parameters in stage I colorectal carcinomas. From the Colorectal Cancer Registry of Modena, we selected two series of patients; the first included all patients who had died of disease progression, the second included patients with a favorable outcome. The histopathological parameters assessed were grade of differentiation, growth pattern at the invasive tumor front, peritumoral lymphocytic infiltration, tumor budding and vascular invasion. The biological variables were proliferative activity (using Ki-67 nuclear antigen), overexpression of p53 protein and altered expression of the mismatch repair proteins (MLH1 and MSH2). The results showed that an infiltrating growth pattern, absent or sparse peritumoral lymphocytic infiltration, the presence of tumor budding and vascular invasion are significantly related to the risk of recurrence. Among the biological parameters, p53 overexpression was significantly correlated with a poor clinical outcome. Our study showed that the histopathologial features are relevant prognostic indicators and might be used as markers for an appropriate treatment strategy in patients with stage I carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860493     DOI: 10.1016/j.prp.2006.05.003

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  17 in total

1.  Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Robert Farkas; Eva Pozsgai; Andrew V Schally; Andras Szigeti; Edit Szigeti; Zoltan Laszlo; Andras Papp; Eva Gomori; Laszlo Mangel; Peter O Horvath; Szabolcs Bellyei
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-08       Impact factor: 4.553

Review 2.  Tumour budding in colorectal cancer: what do we know and what can we do?

Authors:  Linde De Smedt; Sofie Palmans; Xavier Sagaert
Journal:  Virchows Arch       Date:  2015-11-27       Impact factor: 4.064

3.  Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer

Authors:  Richard Garfinkle; Lawrence Lee; Marylise Boutros; Marie-Josee Cardin; Alan Spatz; Nancy Morin
Journal:  Can J Surg       Date:  2019-10-01       Impact factor: 2.089

4.  Lymphovascular invasion in colorectal cancer: an interobserver variability study.

Authors:  Elizabeth I Harris; David N Lewin; Hanlin L Wang; Gregory Y Lauwers; Amitabh Srivastava; Yu Shyr; Bashar Shakhtour; Frank Revetta; Mary K Washington
Journal:  Am J Surg Pathol       Date:  2008-12       Impact factor: 6.394

5.  Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.

Authors:  Chin-Shaw Stella Tsai; Hung-Chang Chen; Jai-Nien Tung; Shung-Sheng Tsou; Tang-Yi Tsao; Ching-Fong Liao; Ying-Chun Chen; Chi-Yuan Yeh; Kun-Tu Yeh; Ming-Chung Jiang
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

6.  Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.

Authors:  Rondell P Graham; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Peter W Laird; Daniel J Weisenberger; Charles F Lynch; Amy J French; Susan L Slager; Yassaman Raissian; Joaquin J Garcia; Sarah E Kerr; Hee Eun Lee; Stephen N Thibodeau; James R Cerhan; Paul J Limburg; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

7.  SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer.

Authors:  Shu-Jing Yu; Jie-Kai Yu; Wei-Ting Ge; Han-Guang Hu; Ying Yuan; Shu Zheng
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

8.  Clinical significance of pT sub-classification in surgical pathology of colorectal cancer.

Authors:  Marion J Pollheimer; Peter Kornprat; Verena S Pollheimer; Richard A Lindtner; Andrea Schlemmer; Peter Rehak; Cord Langner
Journal:  Int J Colorectal Dis       Date:  2009-10-09       Impact factor: 2.571

Review 9.  Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  Oncotarget       Date:  2010-11

10.  Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage.

Authors:  Cheng-Jeng Tai; Tzu-Cheng Su; Ming-Chung Jiang; Hung-Chang Chen; Shing-Chuan Shen; Woan-Ruoh Lee; Ching-Fong Liao; Ying-Chun Chen; Shu-Hui Lin; Li-Tzu Li; Ko-Hung Shen; Chung-Min Yeh; Kun-Tu Yeh; Ching-Hsiao Lee; Hsin-Yi Shih; Chun-Chao Chang
Journal:  J Transl Med       Date:  2013-01-31       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.